bioMerieux : The dream...and the reality
>COVID-19 tests: how much in additional sales? - Tests for COVID-19 could represent a volume of activity close to € 240-250m in 2020 enabling bioMérieux to exceed the targets that it set (growth of +5/+7% and underlying operating profit: € 395-415m) at end February, before the COVID crisis took on the scale that we now see. Moreover, we note that H1 results (publication on 2 September) should be good, despite the charges linked to the variable pay plan indexed to...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.